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Abstract
Background: Elderly population is on rise. It is an ethical dilemma how aggressive one should be
when it comes to treat cancer in elderly. Presumed fear of increased postoperative morbidity and
mortality has resulted in delivery of sub-optimal cancer surgery.
Methods: In this review article we visit physiology of the aged, tools available to assess surgical
risks in oncogeriatric patients, and current practice in the management of common cancers
encountered in surgical oncology, with the view of increasing awareness on optimising surgical
management of senior patients with cancer. A pubmed search for cancer, surgery, elderly, was
carried out.
Results: Cancer is on rise with increasing age predominantly affecting breast, gastrointestinal tract
and lung. Increasingly more surgeons are offering surgery to elderly cancer patient but selection
bias is prevalent. Available data reflect short and long-term outcome of cancer surgery in elderly is
not greatly different to that of younger patient. Declining physiological reserve along with inability
to respond adequately to physiological stress are salient age related changes. Comprehensive
Geriatric Assessment (CGA) is not tested in surgical patient. There is need for a tool to define
individualised operative risk. Preoperative assessment of cancer in elderly is designed to offer this
information based on functional status of an individual utilising currently available tools of risk
assessment.
Conclusion: All elderly cancer patients should be offered optimal treatment depending on their
functional status not on chronological age. Oncogeriatric patient would benefit from dedicated
multidisciplinary approach. Recruitment of elderly cancer patients to more clinical trials is needed
to enhance our knowledge and to offer optimum treatment to this unique subgroup.
Background
The geriatric population is expanding, and hence the clin-
ical decision making are often confused by effects of age-
ing. Age should not be the only parameter considered
when addressing a medical problem [1]. There is much
evidence that the booming elderly population with cancer
does not receive potentially curative treatment afforded to
younger cancer patient [2]. Recently there has been a rise
in the number of articles published related to neoplasm,
surgery and elderly [2]. Several series have proven more
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experience in management of onco-geriatrics. This raising
interest is summarised in Figure 1.
No significant difference in postoperative mortality and
long term survival has been demonstrated, although a
slightly higher morbidity between younger patients
receiving surgical management was detected [2]. How-
ever, one might suspect a selection bias in these series.
This highlights the need for prospective data collection,
including co-morbidities and patient selection. Outcome
of elective cancer operations in elderly could be improved
by taking utmost care around peri-operative period.
In this overview we raise the concern of epidemiological
changes and population dynamics, revisit physiology of
aged, look into currently available instruments to assess
physiology and functional status of elderly oncological
patients, trends in specific organ cancers and their current
treatment. Projected epidemiological data of population
changes in coming years, cancer prevalence in this subset
of population, and current literatures regarding manage-
ment of cancers in elderly, if any, is persuasive enough to
demand for a change. The priority of this issue is to
increase awareness among the medical community and
stimulate a debate about the urge to update the overall
management of elderly oncology patient differently.
Complete management of cancer in this population, and
their eventual outcome, could be improved by specialist
onco-geriatric multidisciplinary team. Preparing medical
community to deal with this impending epidemiological
time bomb is discussed.
Epidemiological outlook
Demographic studies in industrialised countries have
shown a considerable raise in the average life span and a
progressive reduction in birth rates; as a result proportion
of elderly patients is continuously increasing [3,4]. In
developed countries in general, and England and Wales in
particular, more than 15% of population is aged 65 or
over 65 years [3].The demographic changes in developing
countries are leading to rapid increase in the absolute
number of elderly population [5].Average life expectancy
in developing countries has increased from 45 years in
1950 to 64 years by 1995 and is expected to reach 72 years
by 2020 [5]. In most populous developing countries
namely, China, India, and Brazil, people aged 60 years
and over were between 5.9 to 6.8 % in 1970 and are
expected to reach 11 to 15.5% by 2020 [5]. The risk of
developing cancer increases with ageing [6]. The average
age of survival at birth was 40 years at the end of 19th cen-
tury and has now doubled to 81 years for females and 76
years for males and projected to be 86.4 years for males
and 92.3 years for females by 2050 [7]. In census projec-
tion, the high life expectancy series project a US popula-
tion of 416 million by 2050. In this projection 1% would
be over 100 years age (4 million), 7.2 % would be over 85
(30 million), and 23.3% would be over 65 (97 million)
[7], there by accounting for 31.3% of population over 65
years. Currently, average age of survival of a 70 years old
woman is 15 years. A 65 years male is expected to have an
active life expectancy of 12 years and 65 years female
14.09 years [8]. This expansion in life expectancy coupled
with increased incidence of cancer is having a profound
effect on the prevalence of cancer.
The lifetime probability of developing an invasive cancer
is almost 45% in men and 38% in women [9]. The rate of
death from cancer has raised from 17.7% in 1973 to 23%
in 1999, while cardiac disease related death has declined
from 40 % in 1973 to 30% in 1999 [9]. Very soon cancer
will become the leading cause of death and more than
half of new solid cancers cases occur in >70 years [9].
According to SEER data the prevalence of cancer is 207.4
cases/100,000 in <65 years old subjects and 2163.9/
100,000 in >65 years in US [10]. As the incidence of can-
cer increases coupled with improved diagnostic certainty
and life expectancy more doctors will be faced with caring
for elderly patients with cancer.
Despite this epidemiological "time bomb" [11], there is
concern that the scientific community has not been able
to develop a significant amount of evidence-based knowl-
edge. Only a small sub-setting of geriatric patients are
being entered into clinical trials [12-16] thus elderly
patients are still being managed on the basis of assump-
tions based on a younger population group.
This shows the number of Pubmed articles using the search term ; neoplasm, surgery, elderlyFigure 1
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The unstated fear of exposing the frail elderly patient to
increased toxicities, unacceptable morbidities and high
mortality rate can only be minimised and appraised by
improving our insight onto the physiological aspects of
geriatrics.
Ageing is defined as passage of chronological time
whereas senescence is defined as the deteriorative changes
with the time during post-maturation life, i.e. passage of
biological time [17]. Time of onset is affected by multiple
factors like diet, race, sex, physical activity, habits, hormo-
nal effect, etc [17]. The hallmark of senescence is
decreased functional reserve of individual organs and
reduced ability of these organs to cope with the challenge.
The progressive functional inadequacy of physiological
systems is variable from species to species and individual
to individual within the species [17]. It has significant
impact in the peri-operative management of cancer
patients, as well as the tolerance to oncological treat-
ments, i.e. chemotherapy, radiotherapy, major curative
surgery [18,37]. The organ-specific functional deteriora-
tion undoubtedly plays a significant role in the peri-oper-
ative management.
Cardiovascular system
Cardiac output is a product of heart rate and ejection frac-
tion. Ejection fraction is affected by myocardial contractil-
ity and end diastolic filling. Healthy older individuals fail
to increase heart rate to the same extent as younger indi-
viduals at exercise [18]. Basal cardiac output is unchanged
with ageing [18,19]. Ability to increase cardiac output
with ageing is more dependent on ventricular dilatation
i.e., preload [19]. Aged myocardium has lowered sensitiv-
ity to beta adrenergic modulation, physiologically mani-
festing as lower heart rate, and lower cardiac dilatation at
end diastole and end systole [18,19]. Altered pattern of
Calcium regulation allows the older heart myocardium to
generate force for a longer time following excitation,
hence prolongs of systolic phase of cardiac cycle [20]. This
in turn reduces the early diastolic filling rate by half [20].
Incomplete emptying of ventricle at end systole, hence
reduction in ejection fraction is the prominent character-
istics of old heart [20]. Reduced distensability, superim-
posed upon stressed heart could impair coronary
perfusion and hence lead to cardiac ischemia [20,21].
Perioperative fluid depletion in surgical patients in gen-
eral and elderly in particular is not uncommon [20]. This
depletion of intra-vascular volume during peri-operative
period, while undergoing physiological stress is not well
tolerated by elderly [22,23]. Combined effect of depletion
of intra-vascular volume, impaired response to catecho-
lamine and increased myocardium relaxation time
adversely affect the functioning of elderly patient under
stress.
Cardiovascular disease increases with ageing. Cardiac
arrhythmia and conduction abnormalities increase with
ageing. Over half of all postoperative deaths in elderly and
11% of postoperative complications are as a result of
impaired cardiac function under physiological stress
[23,24]. Inexpensive objective tool i.e. supine bicycle exer-
cise test has shown to be very useful for risk stratification
for both pulmonary and cardiac complications prior to
major abdominal and non cardiac surgery in ≥ 65 years
[25]. Identification of this high-risk group is an aim of
Preoperative Assessment of Cancer in Elderly (PACE)
study and their optimisation prior to surgery is the pri-
mary aim of preoperative evaluation.
Respiratory
Changes affecting respiratory functions are as a result of
anatomical-physiological changes affecting chest wall,
respiratory musculature and lung parenchyma and vascu-
lature [26,27]. With ageing maximal voluntary ventila-
tion, Forced Expiratory Volume 1 (FEV 1), Vital Capacity
(VC), decreases [26]. Reductions in blood PO2 Levels,
decreased responsiveness to changes in blood gas levels
and impaired airway protective reflexes are noted [26].
The large reserves and capacities of respiratory system
allow for significant erosion in function with ageing with
minimal impact on normal breathing [27]. However dur-
ing increased demand e.g., exercise that age associated
changes have significant impact on [26]. Reduced lung
elastic recoil with increasing chest wall stiffness results in
decrease in the compliance and increased functional
residual volume [28,29]. With ageing impaired ciliary
function in air passage and general host defence mecha-
nisms compounded by changes in the mechanics of
breathing increases the risk of atelectasis and postopera-
tive pulmonary infections [30]. Literature quotes 9 to 18%
of elderly patients suffer from respiratory complications
during postoperative period after major non-cardiac and
thoracic surgery [25,31]. Aim of preoperative assessment
is to identify this high risk and optimise them prior to
major surgery.
Body composition
Changes in the body weight total body water, body fat dis-
tribution and muscle mass may affect response drug ther-
apy in general and anaesthetic drug in particular.
Proportion of body fat increases with age and is accompa-
nied by concomitant decrease in the total body water and
skeletal muscle mass [32]. As the total body water is
reduced there is a reduction in the volume of distribution
of water soluble drugs. [1,32]. This in association with
decreased renal clearance account for higher plasma levels
of water soluble non-depolarising muscle relaxants in thePage 3 of 14
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in the total body fat affect the distribution of lipid soluble
drugs and could prolong the effect [35].
Fluid, electrolyte and renal physiology
Disorders of fluid and electrolyte balance are very com-
mon in elderly. The homeostatic reserve decreases with
ageing. By the age of 70 years half of the original nephron
complement may have been lost [36]. Loss of renal corti-
cal mass reflects in decline of renal function, decrease in
the glomerular filtration and tubular function and hence
inability to concentrate urine [36]. Serum creatinine may
remain stable masking underlying progressive loss of
renal function [37]. Philip et al, in 1984 demonstrated
decreased thirst sensation in elderly [37]. The renal
responsiveness to vasopressin is impaired, similarly renal
function and renin-aldosterone decreased [37]. Elderly
people under metabolic stress become dehydrated and
acidotic. This compounded by reduced plasma flow and
impaired handling of nephrotoxic drugs renders them
susceptible for acute renal failure [38]. This emphasise the
need to identify high-risk elderly individuals during pre-
operative and Peri-operative time to deliver optimal treat-
ment and to assist them in smooth recovery from surgery.
Liver functions
An elderly patient in general starts with a 20% decrease in
plasma albumin concentration. Peri-operative nutritional
needs of elderly cancer patient deserve special attention
for above reasons. The process of detoxification, conjuga-
tion, and extraction of different compounds seems to be
remarkably preserved under normal conditions despite
actual decrease in the size of the organ. However under
hypermetabolic states, the liver may fail in increasing its
synthetic and metabolic functions [39,40].
Skin and wound healing
The changes seen in aged skin are a combination of effects
from intrinsic and extrinsic factor [41]. Characteristic
changes seen with ageing like dermo-epidermal atrophy,
dryness, roughness, sagging, and wrinkling, have implica-
tions for wound healing [42]. Wound healing in elderly
presents a major clinical and economic problem [42]. Evi-
dence of age-related wound healing has been derived
from most past empirical observation [42]. The clinical
impact of change in the tensile strength of wounds, rate of
wound closure, and accumulation of wound healing in
acute wound healing appears to be small. The consensus
is that effect of ageing on wound repair is primarily a tem-
poral delay and not an actual impairment in the wound
healing. Though there is a temporal delay in healing in
aged it is not any qualitatively different to that of younger
[42]. Poor healing in chronic wounds more often related
to comorbid conditions than age alone.
Function Assessment
Ability to withstand the stress of various forms of treat-
ment for cancer in elderly patient is dependent on the
functional reserve and ability to build an appropriate
response to the stress. A large number of instruments have
been developed over the years by geriatricians, although
some of them are time consuming and impractical in our
busy clinical setting. Amongst the others, we found the
following validated instruments particularly useful in
predicting outcomes in a prospective oncogeriatric series
receiving chemotherapy (table 1) [43])
No scoring method relating to candidacy for surgery has
ever been attempted specifically on oncogeriatric
population.
Surgical risk in elderly
Surgeon is often called to make a decision to operate or
not to operate on a patient and it is one of the most
important decisions that he has to make in surgical prac-
tice. This assumes greater importance when dealing with a
patient who is a poor surgical candidate. In current day
practice there is a high demand for individualised risk
assessment to be shared between the surgeon and patient.
Risk prediction should be appreciated and disclosed to
the patient at the time of consenting.
Chronological age is an unreliable predictor of perform-
ance of health in an individual. The largest numbers of
abnormal laboratory tests are not capable of predicting
post-treatment and operative adverse outcome [49]. Over
half a century ago Welch reported in his large series of
abdominal operation in-patients over 70 years of age, a
peri-operative mortality of 20.7%. He concluded that sur-
gery itself is safe but that aged required greater attention
in peri-operative management [50]. Present evidence sug-
gests that health of extreme elderly is improving and inter-
ventions can be successful at late ages. The Postoperative
mortality, morbidity and long term survival after cancer
surgery for solid tumours are not affected by chronologi-
cal age on its own [51-53]. Currently ongoing multina-
tional study Pre-operative Assessment of Cancer in
Elderly (PACE) is trying to provide a scoring method to
Table 1: Validated instruments in elderly chemotherapy 
patients
Mini Mental Score (MMS) [44]
Activities of Daily Living (ADL) [45]
Instrumental Activities Daily Living (IADL) [46]
Geriatric Depression Scale (GDS) [47]
Brief Fatigue Inventory (BFI) [48]Page 4 of 14
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[54]
Widely known American Society of anaesthesiologists
(ASA) [55] physical status system is not aimed at measur-
ing operative risk, rather it assess globally the degree of
sickness or physical state prior to anaesthesia and surgery.
ASA is insensitive to differentiate largest proportion of
patients in ASA II and III [56]. Surgeons to assess cardiac
risk in non- cardiac surgeries rarely ever use Goldman car-
diac risk index (CRI) [57]. Acute Physiology And Chronic
Health Evaluation (APACHE) is probably the best known
of the physiological scoring systems based on 34 physio-
logical variables taken in the first 24 hours of patient's
admission. APACHE II using 12 physiological variables is
well suited for intensive care unit patients needing venti-
latory support [58]. In general surgical patients' not need-
ing respiratory support its use is limited. Portsmouth
modification of Physiological and Operative Severity
Score for EnUmaration of Mortality and Morbidity (P-
POSSUM) [59] a modification of POSSUM and POSSUM
consists of physiological score and operative score. Latter
component of POSSUM score is highly relevant to the
final outcome; unfortunately necessity of per-operative
variables compromises its usefulness as preoperative
assessment tool.
A comprehensive geriatric assessment (CGA) based on the
previous parenthesis might improve our understanding of
the surgical risk, allowing a more accurate comparison of
surgical series, a careful patient selection, and adequate
consenting.
CGA has proven to be useful in predicting mortality and
morbidity in several clinical settings including hospital
geriatric evaluation, inpatient geriatric consultation,
home assessment service, hospital home assessment serv-
ice and outpatient assessment service and in a number of
chronic diseases [60-63]. It is not a mere list of associated
medical conditions that have impact on prognosis but it
is actually complexity of information that can be gathered
through CGA. CGA adds substantial information to the
functional assessment of elderly cancer patients routinely
collected through performance status (PS) index [60,6].
Preoperative assessment of cancer in elderly (PACE)
An international project has been launched aimed at
defining the general health condition of oncogeriatric sur-
gical candidates. PACE is a tool designed to assess the
functional activities of geriatric patient there by making an
attempt to assess the functional life of an oncogeriatric
patient and there by predicting the individualised risk of
cancer surgery. Patients age 70 years constitute 90% of the
study subjects and present signs of ageing. Patients ≥ 70
years undergoing moderate, major and major + elective
surgery whose mini mental score is 18 and above and are
able to give written informed consent have been included
in this trial. It aims at predicting the probable outcome of
cancer surgery treatment preoperatively in elderly. The
tools incorporated in the PACE are detailed in table 2.
The surgical outcome is defined by 30 day mortality and
30 day morbidity as assessed by care delivery team. The
following complications are included in 30 days morbid-
ity checklist (table 3). Our pilot study has proven PACE is
feasible, inexpensive and well accepted by the patient
(table 4) [64].
Performance status was found to be significantly lower in
patients who developed morbidity and lower activities of
daily living was associated with higher postoperative com-
plications. Recruitment to the study is currently ongoing
and full results will be revealed on completion of this
study [64].
Solid cancers and surgical management
Surgery remains the treatment of choice for solid cancers.
There is significant under representation of elderly in trials
of treatment for lung, colorectal, breast and ovarian can-
cers [65]. In the following paragraphs, we discuss current
trends in the management of common solid tumours
encountered by general surgeon.
Breast cancer
Breast cancer in elderly women is a significant health
problem. Elderly women have 6-fold higher incidence
and 8-fold higher mortality rate compared with non-eld-
erly women [66]. Current incidence rate of breast cancer
remaining constant, it is projected that a 72% increase in
the number of elderly women diagnosed with breast can-
cer in US by 2025 [66]. Fifty percent of breast cancers
occur after the age of 65 years and 25% after the age of 75
years [67]. The number of women diagnosed with breast
cancer is likely to increase due to demographic changes.
Trends in the cancer mortality for all cancers in elderly
Table 2: Validated Instruments Used with PACE
Mini Mental State Examination
Satariano's Modified Index of Comorbidities
Activities of Daily Living
Instrumental Activities of Daily Living
Geriatric Depression Scale
Brief Fatigue Inventory
Eastern Co-operative Oncology Group Performance Status
American Society of Anesthesiologists Physical Status
Physiological and Operative Severity Score for EnUmeration of 
Mortality and Morbidity – (POSSUM)
Portsmouth POSSUM ModificationPage 5 of 14
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cer mortality between ages 65 and 84 has been declining
in the European Union (EU) [68]. Breast cancer mortality
has declined over the last decade by 8% in US and by 3%
in the EU [68].
Our understanding about breast cancer treatment in eld-
erly is mainly based on retrospective and observational
studies and on very few randomised clinical trials [69].
Surgery is the main stay of treatment for early breast can-
cer independent of age and was the usual therapy for all
ages till 1970s [70]. Primary tamoxifen treatment was
adopted enthusiastically in 1980s with publications of
promising early results with tamoxifen in patients over 70
years [71], 81% of elderly women treated with primary
tamoxifen appear to develop progressive disease after 12
years of follow up as against 38% with mastectomy alone
[71].
The drawback of tamoxifen only treatment was the short
duration of response [72]. Patients who relapse face the
prospect of second line hormonal treatment or surgery or
radiotherapy [72]. A change in treatment plan in favour of
surgery is welcome in view of expected active life of 14
years for a 65 years old lady. In general, surgery appears to
be well tolerated despite patient age [71].
Large proportions of elderly cancer patients are offered
less than conventional treatment. Elderly breast cancer
women are offered breast conservative surgery but are less
Table 3: 30 Days Morbidity check
Complications Absent Minor Major
Respiratory
Cardiac failure
Renal failure
Generalized sepsis
Stroke & Neurologic
Haemorrhage & Bleeding
Nutritional problems
Other organ failure
Wound
Infection/Dehiscence/Fistula
Thrombo-embolic
Hepatic failure
Urinary retention
Anastomotic Failure
Peripheral ischemia
Endocrine failure
Pressure Sores
Analgesic problems
Others
Table 4: Pilot study results: Association of PACE with postoperative morbidity
Components Complications 24 patients No complications 48 patients P value
Median (IQR)
Co-morbidities 3.2 (2–5) 3 (2–4) 0.506
MMS 29 (26–30) 27 (26–29) 0.070
GDS 4 (1–7) 2 (1–4) 0.056
BFI 3 (1.1–5.8) 9 (1.3–29.5) 0.216
Number of patients (%)
PS = 0 11 (45.8) 41 (85.4) 0.002
ADL (independent) 4 (16.7) 32 (66.6) <0.001
IADL (dependent) 14 (58.3) 38 (79.2) 0.207
ASA = 1 or 2 17 (70.8) 37 (77.1) 0.681Page 6 of 14
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and chemotherapy [73-75]. Local recurrence rates after
conservative surgery without radiotherapy are reported
between 3 to 47% [76-81]. Mortality rates after breast can-
cer surgery in elderly is <1% [82-84]. Predominant mor-
bidities are related to wound complications [79,83].
Fentiman et al, in their multicentric randomised trail
investigated quality of life (QOL), survival at 12 months
and treatment preferences in elderly patients (≥70 years)
with early breast cancer undergoing mastectomy or
tumour excision plus tamoxifen [85]. Patient undergoing
tumour excision and tamoxifen did not differ from those
undergoing mastectomy in terms of fatigue, emotional
functioning and fear of recurrence. Conservative breast
surgery patients reported fewer arm problems and a bor-
derline shift in the direction of benefit of body image (P =
0.06) [85]. QOL was better after conservative breast sur-
gery and such treatment is to be individualised and to be
preferred independent of age [85].
Axillary surgery plays a key role in management of breast
cancer surgery either to achieve nodal disease control or to
stage the tumour accurately therefore to decide on adju-
vant therapy. Denying axillary surgery exposes the patient
to increased risk of nodal disease recurrence, on the other
hand full axillary clearance increases morbidity. Although
the risk of increased morbidity secondary to full axillary
surgery is not higher in elderly patient [86,87], axillary
surgery is less often undertaken in the elderly patient [88].
Confusion still prevails regarding optimum axillary sur-
gery. To bring new light on this controversy Chetty et al.,
carried out a randomised clinical trial comparing regional
control rate for sampling with axillary clearance. No sig-
nificant difference was found. Unfortunately elderly
patients were excluded from this study [89]. Morbidity
related to axillary surgery in elderly was shown to be no
greater than young. Further research is needed to guide us
in choosing the appropriate axillary surgery for breast can-
cer in this age group.
Primary endocrine treatment has been substituted for sur-
gery based on results from 1980's experience when ER
status was unknown [77], 100% disease progression has
been noted in ER negative group [78,90-92]. Fennessy
concluded that tumour excision decreased the mortality
rate in an unselected population of elderly women with
operable breast cancer who were fit for the procedure [93].
With the current evidence primary endocrine therapy
should be reserved for highly selected ER positive elderly
breast cancer patient who are unfit to have surgery or
respecting patient wishes.
Several retrospective studies have reported age alone
should not determine the type of breast reconstruction.
Autogenous tissue reconstruction can be a safe successful
alternative for women aged 65 year and above [94]. Fur-
ther research is needed to answer outcome of breast recon-
struction after mastectomy for cancer in elderly.
The definition of upper age limit for breast cancer screen-
ing is a very complex issue. Screening benefit depend on
life expectancy. People with < 5–10 years life expectancy
are unlikely to benefit from screening, so it is worth while
considering the variability of different ages. Medical sys-
tem has the ethical obligation to properly inform the pop-
ulation invited for screening. Further research should be
encouraged to answer the benefit of mass population
breast screening in elderly.
The ancient assumption that breast cancer was not worth
resecting in the aged population is finally rejected in view
of a minute morbidity and mortality rate and obviously
improved cancer outcomes for patients who received sur-
gery. It is reassuring to know how the performance of the
largest part of breast surgeons is not significantly biased
by an ageist mentality. There is a need for research target-
ing specific needs of elderly patients with breast cancer
and develop a specific treatment guideline in this group.
Recent survey among breast surgeons in the UK has dem-
onstrated the need of a standardised pre-operative assess-
ment capable of characterising the patient's "functional
age", in order to optimise treatment planning and stratify
outcomes on the basis of factors other than chronological
age [96].
Melanoma
Melanoma is a significant public health problem. Inci-
dence and mortality from cutaneous malignant
melanoma continue to rise [96]. Melanoma is often diag-
nosed late in elderly due to multiple reasons. Many retro-
spective studies have predicted prognosis of melanoma as
age independent [96]. Greater numbers of thick lesions
are increasingly seen with rising age [97]. On the contrary,
Cohen et al, in 1987 predicted age as an independent poor
prognostic factor for death due to melanoma [98]. Litera-
ture search did not yield any prospective randomised trial
to address effect of age on melanoma. With nose and ear
lesions increased [98], the percentage of elderly patients
with metastatic disease at initial diagnosis did not vary
compared to younger individual [98]. Histotype lentigo
maligna lesions were seen with increased frequency in
elderly [97]. Chang et al., in their retrospective evaluation
of intermediate thickness and T4 (≥ 4 mm) melanoma
lesions in ≥ 65 years noted lymph node status is the most
important prognostic factor influencing overall survival
(OS) and disease free survival (DFS) [96,99]. Surgery
plays pivotal role in treating melanoma. The size of resec-
tional safe margins is still being debated in young and eld-
erly alike, but there seems to be no data suggesting a
differentiated approach. Results of retrospective study eld-Page 7 of 14
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adjuvant treatment, did significantly worse than historical
control [96,99] They concluded treatment for melanoma
in ≥ 65 years should be aggressive and should not be
denied adjuvant therapy based on age alone [96,99].
There is no consensus regarding optimal nodal surgery for
melanoma in elderly. Prospective controlled trial is
needed to provide answer to optimum nodal surgery for
cutaneous melanoma in elderly.
Older patients are assumed to have higher risk of compli-
cations from isolated limb perfusion (ILP). Nooda et al.,
did not find significant difference in complete response
rate, loco-regional relapse, limb toxicity, systemic toxicity,
local complications and long term morbidity of ILP
between < 75 years and ≥ 75 years [100]. They concluded
older age is not a contraindication for ILP. It is prudent to
treat melanoma in elderly with same radical approach as
in younger patient without age bias [100].
The predictive value of screening diagnosis of melanoma
was more than twice as high for men ≥ 50 years with either
a changing mole or skin types I and II compared with
other participants [100]. The yield of mass screening for
melanoma could be improved by outreach to middle aged
and older men [101]. Impact of formal assessment of tar-
geted screening warrants a further study.
Lung cancer
Lung cancer is the leading cause of cancer-related deaths
in population aged over 70 years in the western world
[102]. Over half of the people diagnosed with lung cancer
are over 65 years old. Compiled data from 33 countries in
four continents shows increase of 180 % to 580% in the
mortality amongst 65 – 84 years old males and females
with lung cancer respectively from 1955 to 1992 [103]. 25
to 40% of all small cell lung cancer [103] and 40% of non-
small cell lung cancer (NSCLC) [105] are in ≥ 70 year.
Lung cancer mortality rates have declined over last decade
by 8.5% in the EU and by 0.9% in USA [105]. Elderly
cancer patients are less likely to enrol (1.3%) in co-opera-
tive group than younger patients (3.0%) [106]. Surgery
offers the best potential for cure in patients with carci-
noma of the lung, as is the case with most solid tumours.
Patients with untreated or palliated early stage NSCLC
have an average life expectancy of only 1.5 years [107],
while individuals in the ninth decade of life have a 50%
chance of living an additional 5 to 9 more years [108]. In
case of resectable primary lung neoplasms, surgery
remains the treatment of choice independent of age, as is
the case for most solid tumours. No significant difference
in survival or cancer related survival after lobotomy Vs
limited resection has been noted between elderly and
young [109]. Many clinicians avoid surgery or minimise
surgical procedure on the basis of age but recent advances
in the preoperative risk assessment and surgical and
anaesthetic techniques have resulted in a significant
decrease in operative mortality and morbidity [110]. Age
is a recognised risk factor for death after thoracotomy in
elderly patients with lung cancer. Lung sparing procedures
such as segmentectomy and wedge resection are being
increasingly performed for lung cancer especially in eld-
erly patients [111-113]. Recent advances in Video Assisted
Thoracic Surgery (VATS) techniques [114], voice control-
led robotic lung resections [115], provides an alternative
approach to standard thoracotomy in elderly lung cancer
patients resulting in decreased recovery time and fewer
postoperative complications. In a multi institutional trial
of patients with stage I NSCLC undergoing lobectomy by
muscle sparing thoracotomy or VATS confirmed that the
latter approach decreases the incidence of postoperative
complications [116]. Long-term survival after a VATS
lobectomy for NSCLC has been reported to be compara-
ble to that achieved by open thoracotomy [117]. VATS
lobectomy has been proven to be feasible and relatively
safe alternative in-patient with poor cardiopulmonary sta-
tus for early lung cancer [118]. The treatment of stage III
NSCLC is still a matter of debate since the efficacy of sur-
gery decreases and operative mortality increases with stage
of disease. The reluctance to offering surgery for the eld-
erly is particularly evident in these advanced stages that
require more extensive resections. Combined modality
treatments offer an improved outcome for patients with
stage III lung cancer [119]. Unfortunately, elderly patients
have been under represented in these trials. More studies
are warranted in order to define if these conclusions can
be extended to the elderly population as well. The multi-
disciplinary approach to lung cancer acquires importance
when treating elderly patients. The close participation
between pulmonologists, oncologists, thoracic surgeons,
anaesthesiologists, cardiologists, geriatricians, primary
care physicians, physical therapists, and nutritionists on
the pre- and postoperative course of the elderly with lung
cancer can improve measurable outcomes and decrease
their frustrations, therefore improving their quality of life
[118].
Oesophageal cancer
Oesophageal cancer is typically disease of aged man. Esti-
mated annual incidence is 7.7/100,000 in European com-
munity inhabitants. In recent years, the number of elderly
patients with oesophageal cancer has steadily been
increasing. An incidence of 14.5% of all oesophageal can-
cer was seen in years 70 [120]. Our current limited knowl-
edge regarding management of oesophageal cancer in
elderly comes from several retrospective series. Peracchia
et al., reported a consecutive series of 1338 oesophageal
cancer patients of whom 18% were 70 and above, overall
hospital mortality was 6% and five years actuarial survival
rate was 30%. This is comparable to the survival ofPage 8 of 14
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elderly [122]. Hence, they present with complications like
malnutrition and aspiration pneumonia. Some physi-
cians believe that aggressive surgical approach is impru-
dent because of alleged higher rates of mortality and
morbidity and lower rates of survival than younger
patient is. Ellis et al., while reviewing their 27 years expe-
rience from January 1970 to Jan 1997, noted a total of 505
patients had surgery for cancer of oesophagus, 29% of
these were ≥ 70 years. Actuarial 5-year survival rates were
24.1% in ≥ 70 years as against 22.4% in younger patients.
The in-hospital mortality though was higher in elderly
group but was not statistically significant [123]. They con-
cluded age should not be a limiting factor in using aggres-
sive surgical approach for management of cancer of
oesophagus or cardia in patients aged 70 years or older.
Similarly Thomas et al., compared between <70 years and
≥ 70 years, operative mortality (10.7% Vs 11.2%), Major
morbidity (10.7% Vs 13.6%), pulmonary complications
(17.9% Vs 20.6%), and 5-year survival rate (17% Vs
18.9%) and concluded that oesophagectomy can be safely
performed in septuagenarian patients [124]. No differ-
ences in surgical resection rates were noted between
patients younger or older than 70 years [125]. Elderly
patients (>80) had an overall higher respiratory and cardi-
ovascular complications than younger < 70 years. The
operative mortality was 4.7% for < 70 years as against
5.6% for over 80 years. 5-year survival inclusive of
operative mortality was similar 25.1% in over 80 as
against 19.8% in under 70 years [125]. They concluded
that survival benefit is similar to that in younger age
groups enforcing the view that oesophagectomy can be
safely offered in specialist units with acceptable long-term
survival in all ages groups. Long-term survival in oesopha-
geal cancer is related to stage of tumour at presentation
[126] (stage I = 73% Vs stage III = 6%).
There is an urgent need for targeted research and prospec-
tive trial to understand management of oesophageal
cancer in elderly. This could be achieved by active recruit-
ment of elderly oesophageal cancer patients into clinical
trials.
Gastric cancer
Cancer of the stomach is still a common cancer in Europe
with an annual rate of 35.7/100.000. Its incidence peaks
around the age of 70 and is uncommon before the age of
40 years [127]. In elderly, gastric cancer is more likely to
affect the distal part of the stomach [127] and hence there
is a higher prevalence of stenosis and anaemia. Elderly
patients suffer more from a well-differentiated tumour
and frequently of intestinal type [128,129]. There is some
evidence that young patients with gastric cancer have
worse prognosis and have a higher prevalence of diffuse
type [130].
Surgery is the treatment of choice for gastric cancer inde-
pendent of age. The three-year survival rates among octo-
genarians having gastric cancer surgery for advanced and
early gastric group were superior to no surgery group
[131]. The early and long-term outcomes in elderly are
comparable to that of younger patient. Age alone should
not preclude gastric resection in elderly gastric cancer
patients [132].
Due to prevalence of respiratory and cardiovascular co-
morbidity in elderly they are often placed at higher ASA
classes. Maehara claims that the operative mortality has
been significantly reduced in recent years. Reporting on
344 patients who had surgery for gastric cancer, he shows
a drop to 0% in most recently operated patients [133]. The
ratio of partial to total gastrectomy has declined to 60% Vs
40% while the ratio of R0-R1 Vs R2 – R3 has increased
from 45% Vs 65% to 25% Vs 75%. Though the morbidity
is slightly higher than younger age it is not statistically sig-
nificant. The five-year survival does not seem to be
affected by patient's age [133]
Current practice of gastric cancer treatment in elderly is
based upon results from that of younger patient and from
retrospective series. The long-term cancer related progno-
sis of elderly gastric cancer patients does not differ signif-
icantly from that of younger patients, elective surgery
being feasible with standard morbidity.
Colorectal cancer
Colorectal cancer (CRC) is the second most common can-
cer in US, primarily a disease of elderly (138,000 new
cases / year) [134,135] More than half of deaths from
colon and rectal cancer occur in 70 years and above. Its
incidence increases with the increasing age. Based on the
census projection colon cancer related admissions in US
will increase from 192,000 to 448,000 by 2050 in people
aged ≥ 60 years [136]. Median ages at diagnosis ranges
between 70.5 years for colon and 68.4 for rectal cancer
[136]. Association of ColoProctology of Great Britain and
Ireland (ACPGBI) in its recently published booklets has
confirmed high prevalence of cancer in elderly [137]. It
has been shown that patients in the age group of 65–74
were 1.8 times more likely to die following surgery com-
pared with 3.5 times for 75 to 84 years and 5 times for
over 85 years. These odds ratios were not, however,
adjusted for all the other risk factors (ASA, site, and stage)
and should be interpreted with some caution.
Right-sided carcinoma shows an increased frequency in
the older patient [1]. Advanced colorectal tumours are
common in elderly explaining the greater proportion of
palliative surgery in this group [138]. Obstructive
tumours are significantly more common in patients over
70 years of age. Elderly patients with CRC are still present-Page 9 of 14
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tion) in up to 40% of cases. Higher reported incidence of
palliative surgeries being performed, and a lower overall
utilisation of neo-adjuvant preoperative and adjuvant
postoperative therapies; influences long-term cancer
related outcome [139,140]. Elderly rectal cancer patients
continued to be denied surgery i.e., 11% in ≥ 70 years Vs
1% < 70 years [141]. There is paucity of data regarding
adjuvant treatment of older patients with rectal cancer
and hence there is an urgent need to enrol more elderly
rectal cancer patients in to trial to fully evaluate the out-
comes of cancer therapy in this subpopulation [142].
First line of treatment for colorectal cancer is surgery. Total
mesorectal excision (TME) has become new standard of
operative treatment for rectal cancer replacing conven-
tional receptions [143]. Quality of life and functional
results after low anterior resections and TME in the elderly
are of no worse than in younger patient [144], 85% of
patients over 75 years, who had sphincter saving rectal
surgery denied any significant problem with bowel func-
tion or continence [145]. Liver resection for colorectal
cancer liver metastases in properly selected elderly
patients ≥ 70 years is feasible and age alone is not a con-
traindication [146]. Clinico-economical evaluation of
elective colorectal cancer in the aged independently ana-
lysed cost of preoperative investigations, operative real
cost postoperative real costs and median total charges.
The economic burden when delivering radical surgery to
the aged colorectal cancer and younger ones were shown
to be statistically no significant [147]. Five-year cancer
specific survival disease free rates were not different
between young and elderly. Postoperative morbidity and
mean hospital stay were not different between young and
elderly having colorectal surgery [138]. Evidence available
today fails to support the practice of denial of curative
colorectal cancer surgery in elderly under elective
situation. There is very little rationale for substandard
treatment delivery in colorectal cancer surgery, as the
long-term cancer specific survival rates do not differ
according to patients' age under elective conditions
[1,146].
Minimal invasive surgery like laparoscopic assisted colec-
tomy is emerging as alternative to open surgery for colonic
cancer. Early reports shows that it is a viable option and
some elderly patients with CRC have been treated with as
part of these protocols [147]. The safety and efficacy of
laparoscopy assisted colectomy remains unclear, awaiting
the final results of the Clinical Outcomes of Surgical ther-
apy (COST) trial designed to examine whether it is an
effective alternative to open colectomy in the prevention
of recurrence and cancer mortality [148].
The emergency surgery is associated with a significantly
higher incidence of operative mortality at any age (15%
on emergency Vs 5% Elective surgery [1,137]. No signifi-
cant difference in mortality is recorded between two age
groups i.e. <70 years and > 70 years when only elective
operations are considered i.e. 4% and 7.4 % respectively.
Trans-anal excision of low rectal cancer in selected
patients is an acceptable alternative to formal resection.
The recent development of trans-anal endoscopic micro-
surgery (TEMS) has permitted removal of tumours from
the upper rectum. Important selection criteria include
early T stage, good or moderate differentiation, relatively
small tumour size and negative microscopic margins
[150] are factors important in curative resections,
although criteria for deliberately palliative endorectal
resections may be relaxed in selected elderly patients.
Local recurrence and survival rates seem comparable to
TME in early rectal cancer where TEMS is used with cura-
tive intent [151-153].
Conclusion
Surgeons will have to deal with increasing cancers in eld-
erly. Current treatment practices in elderly are based on
experience gained from retrospective series and reviews.
An attempt to transfer the results of younger patients to
this heterogeneous population should be discouraged.
Better understanding of our knowledge about this unique
age group could be achieved by encouraging active partic-
ipation in clinical trials and education of medical commu-
nity. The very finely balanced physiological resources in
elderly cancer patients, demands extreme care around pre-
and peri-operative. The cost of treatment of cancer in eld-
erly is no expensive than those in younger patient. The
enthusiasm to offer cancer treatment to selected oncoger-
iatric patients in par with young, a practice prevalent
among minority of medical community should hence
forth not only include oncogeriatric community without
selection bias but also spread to wider medical commu-
nity members. A currently ongoing multinational trial
(PACE) is aimed at overcoming this selection bias and
assist treating physician to make informed decision about
optimum treatment in discussion with patient. Oncogeri-
atric patients would benefit from complete care with
active participation of multi-disciplinary team comprising
of Surgeons with special interest in geriatric cancer sur-
gery, Geriatricians, Geriatric oncologists, Anaesthetist
with interest in geriatric anaesthesiology and social
worker. Further research into tailored treatment of elderly
cancer patient from the time of preoperative evaluation to
and including optimum surgery for individual cancers
and adjuvant therapy is needed.Page 10 of 14
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Improvement in care of oncogeriatric subgroup comes
with better understanding of elderly cancer patients by
recruiting them into specifically designed clinical trials.
Changing the attitude of treating surgeons towards the
elderly with cancer comes with widening our knowledge.
The benefit of technological advancement should perco-
late to elderly to improve their quality of life aside long-
term survival. The benefit of advancements in science like
early detection of cancers, improvement in anaesthetic
techniques, and surgical techniques, should be extended
based on individual merits independent of age. It is the
responsibility of today's doctors to train future genera-
tions to offer treatment without age bias but on individual
merits. This could be achieved by bringing gerontology in
par with paediatrics to class room teaching. Proactive par-
ticipation of practising doctors and up coming surgeons
in ongoing national and international educational and
scientific meetings should be encouraged.
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